CARBAMAZEPINE LOADED VESICULAR STRUCTURES FOR ENHANCED BRAIN TARGETING VIA INTRANASAL ROUTE: OPTIMIZATION, IN VITRO EVALUATION, AND IN VIVO STUDY

Carbamazepine intranasal vesicular structures

  • GHADA E. YASSIN Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al Azhar University, Cairo, Egypt
  • REHAM I. AMER Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, Egypt
  • AHMED M. FAYEZ Department of Pharmacology, Faculty of Pharmacy, October University for Modern Sciences and Arts (MSA), Giza, Egypt

Abstract

Objective: Carbamazepine (CBZ) is used as a first line in the treatment of grand mal and partial seizures, but it suffers from many side effects on different systems of the body. The objective of the present study was optimization of CBZ vesicular structures using 23 multifactorial design for the most efficient targeting of CBZ to the brain via the intranasal route.


Methods: The concentration of CBZ (10 and 20%), type of vesicles (niosomes and spanlastics) and speed of rotation (200 and 300 rpm) were considered as the independent variables XA, XB and XC respectively, while the dependent variables were particle size PS (Y1), polydispersity index PDI (Y2), zeta potential ZP (Y3) and entrapment efficiency EE (Y4). The study of the effect of different formulation variables was carried out using Design-Expert ® software. CBZ-loaded spanlastics and noisome were prepared by the ethanol injection method and thin film hydration method, respectively. The optimized formulation was subjected to viscosity measurement, in vitro drug release and physical stability studies. In vivo evaluations in rats for the optimized formulation in comparison to oral CBZ suspension was carried out using behavioral assessment by elevated plus maze test, determination of endothelial nitric oxide synthase (e-NOS), reduced glutathione (GSH) and ELISA estimation of TNFα.


Results: The selected optimized formulation (F0) containing 20% CBZ and spanlastic vesicular structure showed PS, PDI, ZP, and the EE % of 350.09 nm, 0.830, 16.124mV and 82.777%, respectively. In vitro release study of F0 demonstrated the ability of the F0 to increase drug release in the range time from 10-60 min (p<0.05) when compared with CBZ suspension. The viscosity of F0 was nearly uniform (65 cps). The photomicrograph taken by the transmission electron microscopy (TEM) reveals the spherical shape of F0. Good physical stability for six months of storage at 25˚ C was found for F0. The optimized spanlastic formulation F0 showed a decrease in latency time in behavior assessment test using elevated plus Maze test, a decrease in serum eNOS and TNF-α and increase in GSH when compared with the oral CBZ suspension, in addition to the histopathological study that revealed the more CBZ uptake by the brain.


Conclusion: The optimized spanlastic formulation F0 achieved better results when compared with the oral CBZ suspension for targeting the CBZ spanlastics vesicular structure to the brain via the nasal route.

Keywords: Optimization, Carbamazepine, Spanlastics, Niosomes, Brain targeting, Elevated Plus Maze Test, Histopathology and Intranasal route

References

1. Karanja SW. Prevalence of emotional and behavioral problems in children with epilepsy attending the child neurology clinic at kenyatta national hospital (Doctoral dissertation, Department of Psychiatry, University of Nairobi); 2017.
2. Durelli L, Massazza U, Cavallo R. Carbamazepine toxicity and poisoning. Med Toxicol Adverse Drug Exp 2012;4:95-107.
3. Ayano G. Bipolar disorders and carbamazepine: pharmacokinetics, pharmacodynamics, therapeutic effects and indications of carbamazepine: review of articles. J Neuropsychopharmacol Ment Heal 2016;1:2.
4. Patel RB, Patel MR, Bhatt KK, Patel BG, Gaikwad RV. Microemulsion-based drug delivery system for transnasal delivery of carbamazepine: preliminary brain-targeting study. Drug Delivery 2016;23:207-13.
5. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem 2009;17:2950–62.
6. Bhatia S. Nanoparticles types, classification, characterization, fabrication methods and drug delivery applications. Nat Polym Drug Delivery Syst Cham: Springer International Publishing; 2016. p. 33–93.
7. Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, et al. Niosomes from 80s to present: the state of the art. Advances in colloid and interface science. 2014;205:187-206.
8. Badawi A, MA Elnabarawi, RTA Elrehem, BA Fayed. Formulation and evaluation of dispersed permethrin proniosomes in powder and microemulsion-based hydrogel bases for the treatment of scabies. Int J Pharm Pharm Sci 2015;8:221-9.
9. Celia C, Cosco D, Paolino D, Fresta M. Nanoparticulate devices for brain drug delivery. Med Res Rev 2011;5:716-56.
10. Bragagni M, Mennini N, Ghelardini C, Mura P. Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. J Pharm Pharm Sci 2012;15:184-96.
11. Kakkar, Kaur. Spanlastics-a novel nanovesicular carrier system for ocular delivery. Int J Pharm 2011;413:202-10.
12. Kaur IP, Rana C, Singh M, Bhushan S, Singh H, Kakkar S. Development and evaluation of novel surfactant-based elastic vesicular system for ocular delivery of fluconazole. J Ocular Pharmacol Ther 2012;28:484-96.
13. Abdelrahman FE, Elsayed I, Gad MK, Elshafeey AH, Mohamed MI. Response surface optimization, ex vivo and in vivo investigation of nasal spanlastics for bioavailability enhancement and brain targeting of risperidone. Int J Pharm 2017;530:1-1.
14. Chandu VP, Arunachalam A, Jeganath S, Yamini K, Tharangini K, Chaitanya G. Niosomes: a novel drug delivery system. Int J Novel Trends Pharm Sci 2012;2:25-31.
15. Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Duodenum-triggered delivery of pravastatin sodium via enteric surface-coated nanovesicular spanlastic dispersions: development, characterization and pharmacokinetic assessments. Int J Pharm 2015;483:77-88.
16. Gaafar PM, Abdallah OY, Farid RM, Abdelkader H. Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone. J Liposome Res 2014;24:204-15.
17. Singh A. An overview of the optimization modelling applications. J Hydrol 2012;466:167-82.
18. Al-Mahallawi AM, Khowessah OM, Shoukri RA. Enhanced non invasive trans-tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: fabrication, in vitro characterization, and comparative ex-vivo permeation studies. Int J Pharm 2017;522:157-64.
19. Obay BD, Ta?demir E, Tümer C, Bilgin HM, Atmaca M. Dose dependent effects of ghrelin on pentylenetetrazole-induced oxidative stress in a rat seizure model. Peptides 2008;29:448-55.
20. Zamani Esmati M, Malakzadeh H, Jenab Esfahani H, Eshaghabadi A, Ghasemi S, Jafarian M. The effect of carbamazepine on neuronal damage in pentylentetrazole model of seizure. Neurosci J Shefaye Khatam 2015;3:42-8.
21. Gülen B, Dur A, Serinken M, Karc?oglu O, Sonmez E. Pain treatment in patients with acute pancreatitis: a randomized controlled trial. Turk J Gastroenterol 2016;27:192-6.
22. Naidu PS, Singh A, Kulkarni SK. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin. Pharmacology 2004;70:59-67.
23. Agarwal NB, Agarwal NK, Mediratta PK, Sharma KK. Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. Seizure 2011;20:257-62.
24. Arhan E, Serdaroglu A, Ozturk B, Ozturk HS, Ozcelik A, Kurt N, et al. Effects of epilepsy and antiepileptic drugs on nitric oxide, lipid peroxidation and xanthine oxidase system in children with idiopathic epilepsy. Seizure 2011;20:138-42.
25. O Olaibi OK, Osuntokun OS, Ijomone OM. Effects of chronic administration of gabapentin and carbamazepine on the histomorphology of the hippocampus and striatum. Ann Neurosci 2014;21:57.
26. Araujo J, Gonzalez Mira E, Egea MA, Garcia ML, Souto EB. Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications. Int J Pharm 2010;393:168-76.
27. Bhalaria MK, Naik S, Misra AN. Ethosomes: a novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol 2009;47:368-75.
28. Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 2010;11:1119-27.
29. Kakar R, Rao R, Goswami A, Nanda S, Saroha K. Proniosomes: an emerging vesicular system in drug delivery and cosmetics. Der Pharmacia Lett 2010;2:227-39.
30. Soliman SM, Abdelmalak NS, El-Gazayerly ON, Abdelaziz N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 23 factorial design and in vivo evaluation in rabbits. Drug Delivery 2016;23:1608-22.
31. A Aboelwafa AA, El-Setouhy DA, Elmeshad AN. Comparative study on the effects of some polyoxyethylene alkyl ether and sorbitan fatty acid ester surfactants on the performance of transdermal carvedilol proniosomal gel using experimental design. AAPS PharmSciTech 2010;11:1591-602.
32. ElMeshad AN, Mohsen AM. Enhanced corneal permeation and antimycotic activity of itraconazole against candida albicans via a novel nanosystem vesicle. Drug Delivery 2016;23:2115-23.
33. Ammar HO, Haider M, Ibrahim M, El Hoffy NM. In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailability enhancement of diltiazem after nasal administration. Drug Delivery 2017;24:414-21.
34. Kamboj S, Saini V, Bala S. Formulation and characterization of drug loaded nonionic surfactant vesicles (niosomes) for oral bioavailability enhancement. Sci World J 2014. http://dx.doi.org/10.1155/2014/959741
35. Basha M, Abd El-Alim SH, Shamma RN, Awad GE. Design and optimization of surfactant-based nanovesicles for ocular delivery of clotrimazole. J Liposome Res 2013;23:203-10.
36. El-Ridy MS, Yehia SA, Mohsen AM, El-Awdan SA, Darwish AB. Preparation, characterization and in vivo evaluation of span 60-lornoxicam niosomes. Res J Pharm Biol Chem Sci 2017;8:398-411.
37. Shukr MH, Eltablawy NA. Development and optimization of novel controlled-release pioglitazone provesicular powders using 32 factorial design. Drug Delivery Translational Res 2015;5:51-62.
38. Al-Mahallawi AM, Khowessah OM, Shoukri RA. Enhanced non invasive trans-tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: fabrication, in vitro characterization, and comparative ex-vivo permeation studies. Int J Pharm 2017;522:157-64.
39. Ahmadirad N, Shojaei A, Javan M, Pourgholami MH, Mirnajafi Zadeh J. Effect of minocycline on pentylenetetrazol-induced chemical kindled seizures in mice. Neurol Sci 2014;35:571-6.
40. Bhardwaj M, Kumar A. Neuroprotective mechanism of coenzyme Q10 (CoQ10) against PTZ induced kindling and associated cognitive dysfunction: possible role of microglia inhibition. Pharmacol Reports 2016;68:1301-11.
41. Gomez CD, Buijs RM, Sitges M. The anti?seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL?1? and TNF?? expression in rat hippocampus. J Neurochem 2014;130:770-9.
42. Lee Y, Shin T. Expression of constitutive endothelial and inducible nitric oxide synthase in the sciatic nerve of lewis rats with experimental autoimmune neuritis. J Neuroimmunol 2002;126:78-85.
43. Kaneko K, Itoh K, Berliner LJ, Miyasaka K, Fujii H. Consequences of nitric oxide generation in epileptic?seizure rodent models as studied by in vivo EPR. Magnetic Resonance Med: Official J Int Soc Magnetic Resonance Med 2002;48:1051-6.
Statistics
204 Views | 106 Downloads
Citatons
How to Cite
YASSIN, G. E., AMER, R. I., & FAYEZ, A. M. (2019). CARBAMAZEPINE LOADED VESICULAR STRUCTURES FOR ENHANCED BRAIN TARGETING VIA INTRANASAL ROUTE: OPTIMIZATION, IN VITRO EVALUATION, AND IN VIVO STUDY. International Journal of Applied Pharmaceutics, 11(4), 264-274. https://doi.org/10.22159/ijap.2019v11i4.33474
Section
Original Article(s)